Please wait...

Quick Stats

Offers Claimed:


Downloaded Today:


Bydureon bcise Prescription
view details
Generic Name: exenatide (ex EN a tide)
Brand Names: Bydureon
Bydureon (exenatide) is an injectable medicine used to treat type 2 diabetes. Includes Bydureon side effects, interactions and indications.
Generic Name: exenatide (ex EN a tide)
Brand Names: Bydureon
Bydureon (exenatide) is an injectable medicine used to treat type 2 diabetes. Includes Bydureon side effects, interactions and indications.
  • Select Your Prescription Settings
  • X
1 tablets of Bydureon Bcise 40 mg
  • Select Your Prescription Settings
  • X

Quick Stats

Offers Claimed: 145

Downloaded Today: 94

Set your location
for drug prices near you

Bydureon Bcise Coupons & Prices

Set your location
for drug prices near you

Enter your ZIP Code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Bydureon Bcise Drug Information:

Bydureon is an extended release injectable Diabetes medicine that helps control blood sugar levels. This medication helps your pancreas produce insulin more efficiently. Bydureon is a long-acting form of exenatide. Bydureon is used together with diet and exercise to improve blood sugar control in adults with type 2 Diabetes mellitus. This medicine is not for treating type 1 Diabetes. This medication guide prOvides information about the Bydureon brand of exenatide. Byetta is another brand of exenatide that is not covered in this medication guide. Learn more

Bydureon Bcise Side Effects

Note: This document contains side effect information about exenatide. Some of the dosage forms listed on this page may not apply to the brand name Bydureon.

In Summary

Common side effects of Bydureon include: diarrhea, nausea, and vomiting. Other side effects include: dizziness, dyspepsia, fidgeting, and headache. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to exenatide: subcutaneous powder for suspension extended release, subcutaneous solution, subcutaneous suspension extended release


Subcutaneous route (Powder for Suspension, Extended Release; Suspension, Extended Release)

Exenatide extended-release causes an increased incidence in thyroid C-cell tumors at clinically relevant exposures in rats compared to controls. It is unknown whether exenatide extended-release causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of exenatide extended-release-induced rodent thyroid C-cell tumors has not been determined.Exenatide extended-release is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of exenatide extended-release and inform them of symptoms of thyroid tumors (eg, mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for detection of MTC in patients treated with exenatide extended-release

Along with its needed effects, exenatide (the active ingredient contained in Bydureon) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking exenatide:

Incidence not known

  • Agitation
  • bloated or feeling of fullness
  • chills
  • confusion
  • constipation
  • cough
  • darkened urine
  • decreased awareness or responsiveness
  • decreased urination or urine output
  • depression
  • difficulty with swallowing
  • dizziness
  • dry mouth
  • fainting
  • fast heartbeat
  • fever
  • headache
  • hives or welts, itching, or skin rash
  • hostility
  • increase in heart rate
  • indigestion
  • irritability
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
  • lightheadedness
  • loss of appetite
  • loss of consciousness
  • muscle twitching
  • nausea
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • rapid breathing
  • rapid weight gain
  • seizures
  • severe sleepiness
  • sunken eyes
  • swelling of the face, ankles, or hands
  • thirst
  • tightness in the chest
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
  • vomiting
  • wrinkled skin
  • yellow eyes or skin

Get emergency help immediately if any of the following symptoms of overdose occur while taking exenatide:

Symptoms of overdose

  • Anxiety
  • blurred vision
  • cold sweats
  • cool, pale skin
  • increased hunger
  • nervousness
  • nightmares
  • severe vomiting
  • shakiness
  • slurred speech

Some side effects of exenatide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Belching
  • diarrhea
  • feeling jittery
  • heartburn
  • stomach discomfort or upset

Less common

  • Decreased appetite
  • increased sweating
  • lack or loss of strength

Incidence not known

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • change in taste
  • excess air or gas in the stomach or intestines
  • loss of taste
  • passing gas
  • pressure in the stomach
  • rash with flat lesions or small raised lesions on the skin
  • redness of the skin
  • sleepiness or unusual drowsiness
  • swelling of the abdomen or stomach area

For Healthcare Professionals

Applies to exenatide: subcutaneous powder for injection extended release, subcutaneous solution, subcutaneous suspension extended release


The most commonly reported side effects have included nausea, vomiting, diarrhea, injection site pruritus, and injection site nodules.


Postmarketing reports: Generalized pruritus and/or urticaria, macular or papular rash, angioedema, anaphylactic reaction


Very common (10% or more): Anti-exenatide (the active ingredient contained in Bydureon) antibodies (up to 90%)


Very common (10% or more): Hypoglycemia (up to 19%)

Common (1% to 10%): Decreased appetite, rapid weight loss (greater than 3.3 lbs/1.5 kg a week), anorexia, hypokalemia

Rare (less than 0.1%): Dehydration (associated with nausea, vomiting and/or diarrhea)


Common (1% to 10%): Urinary tract infection

Postmarketing reports: Altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure or acute renal failure (sometimes requiring hemodialysis), kidney transplant and kidney transplant dysfunction


Very common (10% or more): Injection-site reactions (up to 17.1%)

Common (1% to 10%): Injection-site pain, injection site pruritus, injection site erythema

During clinical trials for the exenatide auto-injector (Bydureon BCISE[R]), injection site nodule was the most commonly reported adverse reaction reported in 10.5% of patients (n=526). Injection site pruritus and injection site erythema were reported in 3.2% and 2.3% of patients, respectively. Injection site nodule was reported as the reason for discontinuation in 0.5% of patients.

Clinical trials comparing immediate-release (Byetta[R]) and extended-release (Bydureon[R]) exenatide have shown that injection-site reactions occurred more frequently in patients treated with extended-release (17.1% vs 12.7%).


Very common (10% or more): Nausea (up to 34%), diarrhea (up to 13%), vomiting (up to 19%)

Uncommon (0.1% to 1%): Intestinal obstruction

Common (1% to 10%): Dyspepsia, constipation, gastroesophageal reflux disease, abdominal distension, abdominal pain, upper abdominal pain, abdominal discomfort, toothache, viral gastroenteritis, gastroenteritis

Very rare (less than 0.01%): Ileus, ischemic colitis, gut ischemia

Postmarketing reports: Eructation, flatulence, acute pancreatitis, hemorrhagic and necrotizing pancreatitis sometimes resulting in death

In clinical trials with the extended-release auto-injector, acute pancreatitis occurred in 0.4% of patients.


Very common (10% or more): Increased heart rate (up to 15%)

Common (1% to 10%): Hypertension

Increases in heart rate of up to 4.5 beats per minute have been observed; long-term effects of increases in heart rate have not been established.


Common (1% to 10%): Hyperhidrosis

Rare (less than 0.1%) Alopecia


Common (1% to 10%): Erectile dysfunction


Common (1% to 10%): Joint pain, back pain, arthralgia, pain in extremity, musculoskeletal pain, muscle spasms

Nervous system

Common (1% to 10%): Headache, dizziness, diabetic neuropathy

Uncommon (0.1% to 1%): Dysgeusia

Rare (less than 0.1%): Somnolence


Common (1% to 10%): Depression, insomnia, anxiety


Very common (10% or more): Nasopharyngitis (up to 19%), upper respiratory tract infection (up to 17%)

Common (1% to 10%): Sinusitis, influenza, cough, oropharyngeal pain


Common (1% to 10%): Fatigue, asthenia, feeling jittery


Rare (less than 0.1%): Increased INR with concomitant warfarin therapy, sometimes associated with bleeding

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/3/2022.

Source: Drugs.com Bydureon Bcise (www.drugs.com/bydureon.html).